Subscribe to RSS
DOI: 10.1055/a-1380-3693
Diagnosis and Treatment of Endometriosis. Guideline of the DGGG, SGGG and OEGGG (S2k Level, AWMF Registry Number 015/045, August 2020)
Article in several languages: English | deutsch- Abstract
- I Guideline Information
- II Guideline Application
- III Methodology
- IV Guideline
- References/Literatur
Abstract
Aims The aim of this official guideline published and coordinated by the German Society of Gynaecology and Obstetrics (DGGG) in cooperation with the Austrian Society for Gynaecology and Obstetrics (OEGGG) and the Swiss Society for Gynaecology and Obstetrics (SGGG) was to provide consensus-based recommendations for the diagnosis and treatment of endometriosis based on an evaluation of the relevant literature.
Methods This S2k guideline represents the structured consensus of a representative panel of experts with different professional backgrounds commissioned by the Guideline Committee of the DGGG, OEGGG and SGGG.
Recommendations Recommendations on the epidemiology, aetiology, classification, symptomatology, diagnosis and treatment of endometriosis are given and special situations are discussed.
#
I Guideline Information
Guideline programme of the DGGG, OEGGG and SGGG
For information about the guideline programme, please refer to the end of the guideline.
#
Citation format
Diagnosis and Treatment of Endometriosis. Guideline of the DGGG, SGGG and OEGGG (S2k Level, AWMF Registry Number 015/045, August 2020). Geburtsh Frauenheilk 2021; 81: 422 – 446
#
Guideline documents
The complete long version together with a slide version of these guidelines and a list of the conflicts of interest of all authors involved are available on the homepage of the AWMF: http://www.awmf.org/guidelinen/detail/ll/015-045.html
#
Guideline group
Author |
AWMF professional society |
---|---|
PD Dr. Stefanie Burghaus |
German Society of Gynaecology and Obstetrics [Deutsche Gesellschaft für Gynäkologie und Geburtshilfe e. V.] (DGGG) |
Dr. Sebastian D. Schäfer |
German Society of Gynaecological Endocrinology and Reproductive Medicine [Deutsche Gesellschaft für Gynäkologische Endokrinologie und Fortpflanzungsmedizin e. V.] (DGGEF) |
Prof. Dr. Uwe Andreas Ulrich |
Society of Gynaecological Endoscopy [Arbeitsgemeinschaft für Gynäkologische Endoskopie] (AGE) |
DGGG working group (AG)/AWMF/non-AWMF professional society/organisation/association |
Mandate holder/author |
Deputy/author |
---|---|---|
Professional Association of Gynaecologists |
PD Dr. med. Stefanie Burghaus |
Prof. Dr. med. Dr. phil. Dr. h. c. mult. Andreas D. Ebert |
German Society for General and Visceral Surgery (DGAV) |
Dr. med. Sebastian D. Schäfer |
|
German Society of Gynaecology and Obstetrics (DGGG) |
Prof. Dr. med. Uwe Andreas Ulrich |
|
German Society of Gynaecological Endocrinology and Reproductive Medicine (DGGEF) |
Dr. med. Volker Heinecke |
|
Society of Gynaecological Endoscopy (AGE) |
Prof. Dr. med. Jan Langrehr |
|
Society of Paediatric and Adolescent Gynaecology |
Prof. Dr. med. Matthias W. Beckmann |
Dr. med. Christine Fahlbusch |
Society of Gynaecological Oncology (AGO) |
Prof. Dr. med. Tanja Fehm |
PD Dr. med. Thomas Papathemelis |
IMed Committee |
Prof. Dr. med. Andreas Müller |
PD Dr. med. Carolin C. Hack |
German Society of Psychosomatic Gynaecology and Obstetrics (DGPFG e. V.) |
PD Dr. med. Friederike Siedentopf |
|
Society of University Reproductive Medicine Centres (URZ) |
PD Dr. med. Andreas Schüring |
Prof. Dr. med. Katharina Hancke |
Medical Society for Health Promotion (ÄGGF) |
Dr. med. Christine Klapp |
Dr. med. Heike Kramer |
German Pathology Society |
Prof. Dr. med. Dietmar Schmidt |
Prof. Dr. med. Lars-Christian Horn |
German Society of Psychosomatic Medicine and Medical Psychotherapy (DGPM) |
Prof. Dr. med. Kerstin Weidner |
PD Dr. med. Christian Brünahl |
German Society for Rehabilitation Sciences |
Dr. Iris Brandes, MPH |
|
German Reproductive Medicine Society (DGRM) |
Prof. Dr. med. Katharina Hancke |
|
German College of Psychosomatic Medicine (DKPM) |
PD Dr. med. Christian Brünahl |
Prof. Dr. med. Kerstin Weidner |
German Radiology Society |
Dr. med. Christian Houbois |
|
German Pain Society |
Prof. Dr. med. Winfried Häuser |
|
German Society of Thoracic Surgery (DGT) |
Dr. med. Wojciech Dudek |
Prof. Dr. med. Dr. h. c. Horia Sirbu |
German Society of Urology |
Dr. med. Isabella Zraik |
|
Austrian Society of Gynaecology and Obstetrics (OEGGG) |
Assoc. Prof. Priv.-Doz. Dr. Beata Seeber |
Prof. Dr. med. Peter Oppelt |
Swiss Society of Gynaecology and Obstetrics (SGGG) |
Prof. Dr. med. Michael Müller |
Dr. med. Peter Martin Fehr |
Czech Society of Gynaecology and Obstetrics |
Prim. Dr. med. Radek Chvatal |
Dr. med. Jan Drahoňovský |
Endometriosis research foundation (SEF) |
Prof. Dr. Dr. h. c. Karl-Werner Schweppe |
Prof. Dr. med. Sylvia Mechsner |
European endometriosis league (EEL) |
Prof. Dr. med. Stefan. P. Renner |
Dr. med. Harald Krentel |
Endometriosis association Germany |
Daniela Soeffge |
Dr. Heike Matuschewski |
Endometriosis association Austria |
Ines Mayer |
Armelle Müller |
Dr. Monika Nothacker, MPH (AWMF Institute for Medical Knowledge Management), who took over moderation of the guideline, is gratefully acknowledged.
#
Gender note
For better readability, simultaneous use of all language forms is omitted throughout. All female or male references to persons apply to each sex.
#
Abbreviations employed
#
#
II Guideline Application
Purpose and objectives
The purpose of this guideline is to provide information and advice about the diagnosis, treatment and further care of endometriosis as well as specific situations for women with already confirmed or suspected endometriosis and for physicians who treat women with endometriosis.
In addition, the information is intended to form the basis for joint decision-making in certified endometriosis clinics, units or centres. The defined statements and recommendations will also be used to develop quality indicators.
#
Area of patient care
Inpatient, outpatient and day-care sector.
#
Target user group/target audience
This guideline is aimed at the following groups: office-based gynaecologists, gynaecologists in hospitals, reproductive medicine physicians, pathologists, urologists, visceral surgeons, radiologists, psychosomatic specialists and psychologists, pain therapists, patients with or suspected to have endometriosis, specialists in rehabilitation medicine, general physicians, paediatricians and womenʼs interest groups that represent womenʼs interests (patient and self-help organisations).
Additional targeted groups (for information purposes): nursing staff, members of occupational groups involved in the care of patients with confirmed or suspected endometriosis (e.g., stoma therapists), funding bodies and German national and regional health policy institutions and decision-makers.
#
Adoption and period of validity
The validity of this guideline was confirmed by the executive boards/heads of the participating professional societies/working groups/organisations/associations, as well as by the boards of the DGGG and the DGGG Guidelines Commission and of the SGGG and OEGGG in July 2020 and was thus approved in its entirety. This guideline is valid from 01.08.2020 to 31.07.2023. Because of the contents of this guideline, this period of validity is only an estimate.
#
#
III Methodology
Basic principles
The method used to prepare this guideline was determined by the class to which this guideline was assigned. The AWMF Guidance Manual (version 1.0) has set out the respective rules and requirements for different classes of guidelines. Guidelines are differentiated into the lowest (S1), intermediate (S2) and highest (S3) class. The lowest class is defined as a set of recommendations for action compiled by a non-representative group of experts. In 2004, the S2 class was divided into two subclasses: a systematic evidence-based subclass (S2e) and a structural consensus-based subclass (S2k). The highest S3 class combines both approaches.
This guideline was classified as: S2k.
#
Grading of recommendations
Grading of evidence based on the systematic search, selection, evaluation and synthesis of the evidence base followed by a grading of the evidence is not envisaged for S2k-level guidelines. The individual statements and recommendations are only differentiated by syntax, not by symbols ([Table 3]):
Description of binding character |
Expression |
---|---|
Strong recommendation, highly binding |
must/must not |
Recommendation, moderately binding |
should/should not |
Open recommendation, not binding |
may/may not |
#
Statements
Expositions of explanations of specific facts, circumstances or problems without any direct recommendations for action included in this guideline are referred to as “Statements”. It is not possible to provide any information about the grading of evidence for these statements.
#
Achieving consensus and strength of consensus
At structured NIH-type consensus-based conferences (S2k/S3 level), authorised participants attending the session vote on draft statements and recommendations. The process is as follows. A recommendation is presented, its contents are discussed, proposed changes are put forward, and finally, all proposed changes are voted on. If a consensus has not been achieved (≤ 75% of votes), there is another round of discussions, followed by a repeat vote. Finally, the extent of consensus is determined based on the number of participants ([Table 4]).
Symbol |
Strength of agreement |
Extent of agreement in percent |
---|---|---|
+++ |
Strong consensus |
> 95% of participants agree |
++ |
Consensus |
> 75 – 95% of participants agree |
+ |
Majority agreement |
> 50 – 75% of participants agree |
– |
No consensus |
< 51% of participants agree |
#
Expert consensus
As the name already implies, this refers to consensus decisions taken with regard to Recommendations/Statements without a prior systematic search of the literature (S2k) or for which evidence is lacking (S2e/S3). The term “expert consensus” (EC) used here is synonymous with terms used in other guidelines such as “good clinical practice” (GCP) or “clinical consensus point” (CCP). The strength of the recommendation is graded as previously described in the section “Grading of recommendations”, i.e., purely semantically (“must”/“must not” or “should”/“should not” or “may”/“may not”) and without the use of symbols.
#
#
IV Guideline
1 Epidemiology, aetiology, morbidity and manifestation of endometriosis
Figures on the prevalence and incidence vary according to the clinical situation and are also influenced by selective consideration.
Reliable data on the prevalence and incidence of endometriosis are not available.
Different concepts were developed to describe the possible causes for the development and persistence of the disease (e.g., implantation theory [1], coelom metaplasia theory [2], archimetra or “tissue injury and repair concept” [3], [4], but without finding a satisfactory final explanation. Rather, from combining the various concepts, it is assumed that genetic defects and epigenetic phenomena as well as other influences provide the conditions for specific changes to take place during implantation and metaplasia that will allow foci of endometriosis to develop in a milieu that is foreign for these cells. Important factors influencing this process include hyperperistalsis, arising from adaptations due to evolutional biology [4], hyperoestrogenisation, hyperperistalsis, inflammatory and immune processes, prostaglandin metabolism, angiogenesis, oxidative stress and various others [5], [6], [7].
Because of the unclear aetiology of endometriosis, causal therapy is not possible.
Reference: [8]
The following are affected in decreasing frequency: pelvic peritoneum, ovaries, sacrouterine ligaments, rectovaginal septum/vaginal fornix, extragenital manifestations (e.g., rectosigmoid and bladder).
#
2 Basic principles of endometriosis classification (clinical/intraoperative, histological, DRG system)
2.1 Clinical/intraoperative classification of endometriosis
A clinical/intraoperative distinction depending on the location and extent is made between the following endometriosis entities: peritoneal endometriosis, ovarian endometriosis, deep infiltrating endometriosis (DIE) and uterine adenomyosis.
If an intraoperative diagnosis of endometriosis is suspected, the diagnosis must be confirmed histologically.
The rASRM score (version 1996) must be documented at all operations on patients with a suspected diagnosis of endometriosis.
The Enzian classification (version 2011) must be used in patients with deep infiltrating endometriosis including uterine adenomyosis.
The symptoms pain and infertility are not recorded with the rASRM score and the Enzian classification. The classifications also do not predict the course of the disease.
#
2.2 Histological classification of endometriosis
Endometriosis is the occurrence of endometrium-like groups of cells consisting of groups of endometrioid glandular cells and/or stromal cells outside the uterine cavity.
The primary histological diagnosis of endometriosis is made by haematoxylin-eosin staining. If histological diagnosis of macroscopically suspected endometriosis is negative, additional tests (e.g., additional sections, CD10 or haemosiderin staining) should be performed.
Endometriosis of the body of the uterus (clinically: adenomyosis or uterine adenomyosis or internal genital endometriosis) is defined histopathologically as the finding of a focus of endometriosis in the myometrium at a distance from the endo-myometrial boundary at medium magnification (100 ×) equivalent metrically to 2.5 mm.
In bowel specimens resected because of deep infiltrating endometriosis involving bowel, a statement about the resection margin status must be made in the histopathological report.
#
2.3 DRG system of endometriosis (ICD-10-GM-2019, OPS-2019)
Endometriosis is classified in the DRG system according to ICD-10-GM-2019 and this forms the basis of the consideration of endometriosis sites in section 6 ff below.
#
#
3 Symptoms and basic principles of diagnosis of endometriosis (investigation algorithm)
Endometriosis-specific symptoms (dysmenorrhoea, dysuria, dyschezia, dyspareunia and infertility) and nonspecific symptoms such as pelvic pain must be recorded when taking a gynaecological history. This can be done with a specific endometriosis questionnaire.
Reference: [12]
If deep infiltrating endometriosis or ovarian endometriosis is suspected, bilateral renal ultrasound must be performed.
Reference: [13]
Biomarkers are not suitable for the diagnosis of endometriosis.
Reference: [8]
#
4 Basic principles of treatment of endometriosis
4.1 Hormonal treatment of endometriosis
The principle of effective hormonal treatment consists of induction of therapeutic amenorrhoea. In German-speaking countries, only the progestin dienogest and the gonadotropin-releasing hormone (GnRH) analogue leuprorelin acetate have been approved to date for the hormonal treatment of endometriosis.
A suitable progestin (e.g., dienogest) should be used as first-line drug in the symptomatic pharmacological treatment of endometriosis.
-
Combined oral contraceptives (strength of consensus ++)
-
Other progestins including topical use (strength of consensus +++) or
-
GnRH analogues (strength of consensus ++)
can be used as second-line treatment.
Before starting second-line treatment, re-evaluation in a facility specialising in the care of patients with endometriosis should be considered.
Long-term hormonal therapy used continuously is effective both in the treatment of endometriosis-associated symptoms and for prolonging the recurrence-free interval.
Reference: [8]
Primary hormonal therapy
There have been increasing attempts to use progestins and oral contraceptives as first-line treatment prior to surgical diagnosis or treatment. There was no significant difference between primary pharmacological and operative therapy in pain relief [17]. However, valid data are lacking that would allow assessment in the long term of symptom relief, the probability of recurrence and the influence on fertility with primary hormonal therapy.
#
Postoperative hormonal therapy
The rate of endometrioma recurrence and the rate of symptoms such as dysmenorrhoea and chronic pain can be reduced by postoperative therapy with combined oral contraceptives in a long-term cycle [18]. This was also shown for dienogest [19]. Use of GnRH analogues for 6 instead of 3 months significantly reduced the risk of recurrence [20].
#
#
4.2 Pharmacological, non-hormonal therapy of endometriosis
Analgesics
Analgesics are used for the symptomatic treatment of patients with pain. In a Cochrane review from 2017 the use of nonsteroidal anti-inflammatory drugs (NSAIDs) in patients with endometriosis was analysed. Only two randomised controlled studies were identified, so that a conclusion regarding the effectiveness of NSAIDs and also subgroup analyses are not possible. The data regarding NSAIDs for (primary) dysmenorrhoea are much better and NSAIDs appear to be effective for the relief of menstrual pain [21].
#
#
4.3 Surgical treatment of endometriosis
In the symptomatic patient with deep infiltrating endometriosis, complete resection should be attempted if the expected benefits of pain reduction outweigh the disadvantages of possible operation-related organ impairment (e.g., sexuality and disorders of bladder, bowel, sensory and motor function).
Reference: [17]
For recurrent symptoms, pharmacological treatment should be given before further surgical treatment unless there are compelling reasons for surgery (e.g., organ destruction).
Reference: [17]
#
#
5 Care structures for patients with suspected or confirmed endometriosis
Patients with endometriosis should be treated by an interdisciplinary team. This team should include all necessary specialties in a cross-sector network. This can be achieved in a certified structure (clinic, centre) ([Fig. 1]).
![](https://www.thieme-connect.de/media/gebfra/202104/thumbnails/10-1055-a-1380-3693-i13803693gf01.jpg)
![Zoom Image](/products/assets/desktop/css/img/icon-figure-zoom.png)
#
6 Diagnosis and treatment of endometriosis according to site
6.1 Endometriosis of the uterus (N80.0)
The suspected diagnosis adenomyosis of the uterus can be made by transvaginal sonography and/or MRI. Transvaginal sonography must be used as first-line diagnostic investigation, and MRI as second-line investigation. Both methods are equivalent as regards their reliability.
Because of the limited sensitivity and specificity of biopsy-based confirmation of adenomyosis of the uterus, a biopsy should not be done.
All established forms of hormone therapy (combined oral contraceptives, progestins, suitable progestin IUD, GnRH analogues) are effective in the treatment of adenomyosis-associated symptoms. There is no evidence that one substance class is superior.
Interventional treatment with high-frequency ultrasound (HIFU), uterine artery embolisation (UAE), transcervical electroablation, percutaneous microwave ablation (PMWA) to treat adenomyosis of the uterus must be used only in studies.
Cystic or focal adenomyosis of the uterus can be resected for control of pain and bleeding.
Hysterectomy can be recommended for symptoms of adenomyosis of the uterus when family planning is complete.
Reference: based on the S3 guideline “Indication and method of hysterectomy for benign disease” in version 1.0 April 2015, AWMF no. 015/070 with weakening of the level of recommendation.
#
6.2 Endometriosis of the ovary and tube (N80.1 and N80.2)
The potential negative influence of the endometrioma on ovarian reserve and function is probably caused by stretching of the ovarian cortex, local inflammatory processes, oxidative stress and fibrosis of the ovary [22].
Before determining the treatment strategy for ovarian endometriosis, anti-Müllerian hormone can be measured as a marker of ovarian reserve.
Ovarian function must be considered when deciding on the treatment of endometriomas.
When endometriomas are removed in cases of recurrence, there is an increased risk for premature loss of ovarian function.
All known operative procedures for endometriomas reduce ovarian reserve.
When an endometrioma is diagnosed, the simultaneous presence of deep infiltrating endometriosis should be excluded.
Transvaginal sonography must be used to assess the ovaries when endometriosis is confirmed or suspected.
If the result of sonography of the ovary is suspicious, the surgical histological diagnosis must be confirmed observing oncological safety.
To prevent endometrioma recurrence, systemic hormone therapy (preferably with COC) can be used long-term.
With primary surgical treatment of an endometrioma, complete removal compared with fenestration of the ovary increases the spontaneous pregnancy rate and is superior to pharmacological treatment with regard to pain reduction and avoidance of recurrence.
If assisted reproduction is planned, the prospect of success is probably not increased by prior endometrioma removal [22], [23].
#
6.3 Endometriosis of the pelvic peritoneum/peritoneal endometriosis (N80.3)
If symptomatic peritoneal endometriosis is diagnosed intraoperatively, primary complete removal should be attempted. Planned second-look laparoscopy with or without pretreatment must not be performed.
Ablation and excision of peritoneal endometriosis are equivalent with regard to pain reduction.
Reference: [24]
Surgical removal of peritoneal endometriosis leads to a significant reduction in the severity of dysmenorrhoea on the visual analogue scale (VAS). This effect was not shown for chronic pelvic pain, dyschezia and dyspareunia when peritoneal endometriosis was removed surgically.
Reference: [24]
#
6.4 Endometriosis of the rectovaginal septum and vagina (N80.4)
For symptomatic endometriosis of the rectovaginal septum and vagina, function-adapted complete resection should be performed.
Asymptomatic endometriosis of the rectovaginal septum and vagina without currently foreseeable, clinically significant secondary consequences (e.g., obstructive uropathy) does not have to be treated.
#
6.5 Endometriosis of the bowel (N80.5)
A patient with haematochezia must have differential diagnostic investigations.
An asymptomatic patient with bowel endometriosis does not require any surgical intervention.
A patient with bowel endometriosis must be treated in interdisciplinary consensus, in certified facilities as far as possible.
In patients with endometriosis of the bowel renal sonography must be performed in the case of conservative treatment or pre- and postoperatively so as not to overlook clinically silent hydronephrosis.
#
6.6 Endometriosis in a skin scar (N80.6)
Surgical removal of an endometriosis lesion in a skin scar leads to symptom control and is the treatment of choice.
#
6.7 Endometriosis in the bladder and of the ureter (N80.8)
Endometriosis of the bladder and/or ureter can have serious consequences, such as obstructive uropathy with potential consequent loss of renal function.
Even though isolated cases of endometriosis of the bladder treated pharmacologically are described in the literature [25], the treatment of endometriosis of the bladder in most cases consists of partial cystectomy [26], [27]. If the endometriosis nodule is located in proximity to the ureter ostia, a double J catheter is inserted immediately before the intervention.
In the case of endometriosis of the ureter, the first step is to attempt ureter decompression without segment resection or ureter implantation; ureteroneocystostomy should be performed only if this fails and the ureter and renal pelvis do not recover.
#
6.8 Rare extragenital endometriosis locations, extra-abdominal endometriosis (N80.8)
Symptomatic abdominal wall or umbilical endometriosis should be removed surgically.
For thoracic endometriosis and/or endometriosis-associated pneumothorax (including catamenial pneumothorax), conservative pharmacological measures should be used initially. If medical treatment fails or is contraindicated, thoracic surgery must be performed.
#
#
7 Special endometriosis situations
7.1 Endometriosis in adolescents
All forms of persistent pelvic pain (dysmenorrhoea, cyclical and non-cyclical pelvic pain) in adolescence can be symptoms of endometriosis.
The primary treatment of suspected endometriosis in adolescence should be conservative pharmacological treatment.
For refractory pain, laparoscopy should be performed to investigate the symptoms and, if applicable, remove any endometriosis, if possible in the same procedure.
#
7.2 Endometriosis and desire for children
Women with histologically confirmed endometriosis should be informed about the possibly impaired chances of pregnancy.
For patients with infertility and endometriomas, treatment should be determined in an interdisciplinary setting in collaboration with a reproductive medicine centre.
#
7.3 Endometriosis: pregnancy and delivery
With regard to pregnancy, there is now a fairly large number of studies that present the increased risks as follows:
-
Miscarriage rate [28]
-
Pre-term birth [29]
-
Premature rupture of the membranes [30]
-
Premature placental abruption [31]
-
Placenta previa [31]
-
Preeclampsia risk – varying opinions [32]
-
SHIP – sudden haemoperitoneum in pregnancy (very rare) [33]
-
Gestational diabetes [34]
Treated or existing deep infiltrating endometriosis is not a contraindication to spontaneous delivery.
In the case of existing or resected rectal endometriosis, no recommendation for a certain mode of delivery (i.e., spontaneous delivery versus section) can be expressed.
Surgical treatment of deep infiltrating endometriosis in the region of the sigmoid, appendix/caecum, ileum or colon is not an indication for primary section.
#
7.4 Endometriosis and pain
In patients with chronic pelvic pain, symptom-guided pain therapy can be considered in the following situations:
-
Insufficient pain reduction and/or
-
Intolerance and/or
-
Contraindications to surgical or hormonal therapy.
#
7.5 Endometriosis and cancer
A patient with endometriosis has a very low risk overall of developing ovarian cancer because of the only slightly increased ovarian cancer risk as the lifetime risk of this is low anyway at 1.3%. In most of the published studies on endometriosis-associated ovarian cancer (EAOC), the risk of the disease in endometriosis patients is classified as moderate (RR, SIR or OR: 1.3 – 1.9) [37], [38], [39]. Unilateral salpingo-oophorectomy can be discussed, however, e.g., in perimenopausal women with endometriomas > 6 – 9 cm, since the risk of ovarian cancer in these patients is increased up to 13.2 times. Removal of the endometrioma alone does not reduce the risk in this group of patients [40].
The terminology and morphological diagnosis of endometriosis-associated cancer must be based on the current version of the WHO classification.
The surgical treatment concept for patients with endometriosis in the premenopause should not be influenced by the slightly increased ovarian cancer risk.
#
7.6 Endometriosis and psychosomatic aspects
Primary psychological assessment for anxiety and depression in patients with endometriosis should take place in the context of basic psychosomatic care.
Patients with endometriosis and high stress due to mental symptoms must be offered psychotherapy, if possible within a multimodal treatment concept.
#
7.7 Endometriosis and association with other diseases
Patients with endometriosis and chronic pelvic pain must be investigated for the presence of other chronic pain syndromes.
In the gynaecological examination, local (myofascial trigger points) and generalised hyperalgesia and increased pain sensitivity (allodynia) as evidence for central sensitisation must be noted.
In patients with endometriosis and associated pain syndromes, treatment options must be discussed with pain therapists and physicians specialising in psychosomatic medicine and psychotherapy or psychological psychotherapists.
#
#
8 Rehabilitation, follow-up care and self-help
Rehabilitation/follow-up treatment for women with endometriosis should take place in a rehabilitation clinic certified for this disease.
Reference: [47]
Women with endometriosis must be informed of the services provided by the pension insurance organisations for rehabilitation and follow-up care.
Reference: [48]
#
9 Integrative therapy in patients with endometriosis
There are a few small prospective randomised studies that investigated the different integrative therapy methods with regard to the effectiveness of pain reduction in primary dysmenorrhoea, though evidence of existing endometriosis very rarely had to be provided in these studies. The pain reduction was mainly in the placebo, comparator or control group and the active treatment group was rarely superior. The number of included patients/participants was usually rather low. The maximum study period or follow-up period was 6 to 12 months. The data are insufficient with regard to fertility.
Various Chinese herbal medicines, calcium, phototherapy, acupuncture, electroacupuncture, moxibustion, injection of local anaesthetics into pain trigger points, manual therapy and physical exercise can be used for the primary treatment of primary dysmenorrhoea.
Endometriosis patients should be asked about the use of complementary medicine and alternative methods and advised if they wish.
Patients who use such methods must be informed of possible risks and, where applicable, interactions with standard treatments.
#
#
![](https://www.thieme-connect.de/media/gebfra/202104/thumbnails/10-1055-a-1380-3693-igf_ll.jpg)
![Zoom Image](/products/assets/desktop/css/img/icon-figure-zoom.png)
#
Conflict of Interest/Interessenkonflikt
The conflicts of interests of the authors are listed in the long version of the guideline./Die Interessenkonflikte der Autoren sind in der Langfassung der Leitlinie aufgelistet.
-
References/Literatur
- 1 Sampson JA. Metastatic or Embolic Endometriosis, due to the Menstrual Dissemination of Endometrial Tissue into the Venous Circulation. Am J Pathol 1927; 3: 93-110.43
- 2 Meyer R. Über den Stand der Frage der Adenomyositis, Adenomyome im allgemeinen und insbesondere über Adenomyositis seroepithelialis und Adenomyometritis sarcomatosa. Zentralbl Gynäkol 1919; 36: 745-750
- 3 Leyendecker G, Kunz G, Noe M. et al. Endometriosis: a dysfunction and disease of the archimetra. Hum Reprod Update 1998; 4: 752-762
- 4 Leyendecker G, Wildt L, Mall G. The pathophysiology of endometriosis and adenomyosis: tissue injury and repair. Arch Gynecol Obstet 2009; 280: 529-538
- 5 Gordts S, Koninckx P, Brosens I. Pathogenesis of deep endometriosis. Fertil Steril 2017; 108: 872-885.e1
- 6 Koninckx PR, Ussia A, Adamyan L. et al. Pathogenesis of endometriosis: the genetic/epigenetic theory. Fertil Steril 2019; 111: 327-340
- 7 Parazzini F, Esposito G, Tozzi L. et al. Epidemiology of endometriosis and its comorbidities. Eur J Obstet Gynecol Reprod Biol 2017; 209: 3-7
- 8 Hirsch M, Begum MR, Paniz E. et al. Diagnosis and management of endometriosis: a systematic review of international and national guidelines. BJOG 2018; 125: 556-564
- 9 Clement PB, Young RH. Atlas of Gynecologic Surgical Pathology. 4th ed. Edinburgh, London, New York, Oxford, Philadelphia, St. Louis, Sydney: Elsevier; 2020: 183-184
- 10 Cockerham AZ. Adenomyosis: a challenge in clinical gynecology. J Midwifery Womens Health 2012; 57: 212-220
- 11 McCluggage WG, Robboy SJ. Mesenchymal uterine tumors, other than pure smooth muscle neoplasms, and adenomyosis. In: Robboyʼs Pathology of the Female Reproductive Tract. 2nd ed.. Churchill Livingstone; 2008: 450-456
- 12 Burghaus S, Fehm T, Fasching PA. et al. The International Endometriosis Evaluation Program (IEEP Study) – A Systematic Study for Physicians, Researchers and Patients. Geburtshilfe Frauenheilkd 2016; 76: 875-881
- 13 Palla VV, Karaolanis G, Katafigiotis I. et al. Ureteral endometriosis: A systematic literature review. Indian J Urol 2017; 33: 276-282
- 14 Schliep KC, Chen Z, Stanford JB. et al. Endometriosis diagnosis and staging by operating surgeon and expert review using multiple diagnostic tools: an inter-rater agreement study. BJOG 2017; 124: 220-229
- 15 Wu D, Hu M, Hong L. et al. Clinical efficacy of add-back therapy in treatment of endometriosis: a meta-analysis. Arch Gynecol Obstet 2014; 290: 513-523
- 16 Tsai HW, Wang PH, Huang BS. et al. Low-dose add-back therapy during postoperative GnRH agonist treatment. Taiwan J Obstet Gynecol 2016; 55: 55-59
- 17 Chaichian S, Kabir A, Mehdizadehkashi A. et al. Comparing the Efficacy of Surgery and Medical Therapy for Pain Management in Endometriosis: A Systematic Review and Meta-analysis. Pain Physician 2017; 20: 185-195
- 18 Zorbas KA, Economopoulos KP, Vlahos NF. Continuous versus cyclic oral contraceptives for the treatment of endometriosis: a systematic review. Arch Gynecol Obstet 2015; 292: 37-43
- 19 Adachi K, Takahashi K, Nakamura K. et al. Postoperative administration of dienogest for suppressing recurrence of disease and relieving pain in subjects with ovarian endometriomas. Gynecol Endocrinol 2016; 32: 646-649
- 20 Zheng Q, Mao H, Xu Y. et al. Can postoperative GnRH agonist treatment prevent endometriosis recurrence? A meta-analysis. Arch Gynecol Obstet 2016; 294: 201-207
- 21 Marjoribanks J, Ayeleke RO, Farquhar C. et al. Nonsteroidal anti-inflammatory drugs for dysmenorrhoea. Cochrane Database Syst Rev 2015; (07) CD001751 DOI: 10.1002/14651858.CD001751.pub3.
- 22 Keyhan S, Hughes C, Price T. et al. An Update on Surgical versus Expectant Management of Ovarian Endometriomas in Infertile Women. Biomed Res Int 2015; 2015: 204792
- 23 Tao X, Chen L, Ge S. et al. Weigh the pros and cons to ovarian reserve before stripping ovarian endometriomas prior to IVF/ICSI: A meta-analysis. PLoS One 2017; 12: e0177426
- 24 Riley KA, Benton AS, Deimling TA. et al. Surgical Excision Versus Ablation for Superficial Endometriosis-Associated Pain: A Randomized Controlled Trial. J Minim Invasive Gynecol 2019; 26: 71-77
- 25 Angioni S, Nappi L, Pontis A. et al. Dienogest. A possible conservative approach in bladder endometriosis. Results of a pilot study. Gynecol Endocrinol 2015; 31: 406-408
- 26 Ceccaroni M, Clarizia R, Ceccarello M. et al. Total laparoscopic bladder resection in the management of deep endometriosis: “take it or leave it.” Radicality versus persistence. Int Urogynecol J 2019; DOI: 10.1007/s00192-019-04107-4.
- 27 Knabben L, Imboden S, Fellmann B. et al. Urinary tract endometriosis in patients with deep infiltrating endometriosis: prevalence, symptoms, management, and proposal for a new clinical classification. Fertil Steril 2015; 103: 147-152
- 28 Hjordt Hansen MV, Dalsgaard T, Hartwell D. et al. Reproductive prognosis in endometriosis. A national cohort study. Acta Obstet Gynecol Scand 2014; 93: 483-489
- 29 Kim SG, Seo HG, Kim YS. Primiparous singleton women with endometriosis have an increased risk of preterm birth: Meta-analyses. Obstet Gynecol Sci 2017; 60: 283-288
- 30 Conti N, Cevenini G, Vannuccini S. et al. Women with endometriosis at first pregnancy have an increased risk of adverse obstetric outcome. J Matern Fetal Neonatal Med 2015; 28: 1795-1798
- 31 Berlac JF, Hartwell D, Skovlund CW. et al. Endometriosis increases the risk of obstetrical and neonatal complications. Acta Obstet Gynecol Scand 2017; 96: 751-760
- 32 Zullo F, Spagnolo E, Saccone G. et al. Endometriosis and obstetrics complications: a systematic review and meta-analysis. Fertil Steril 2017; 108: 667-672.e5
- 33 Vigano P, Corti L, Berlanda N. Beyond infertility: obstetrical and postpartum complications associated with endometriosis and adenomyosis. Fertil Steril 2015; 104: 802-812
- 34 Lalani S, Choudhry AJ, Firth B. et al. Endometriosis and adverse maternal, fetal and neonatal outcomes, a systematic review and meta-analysis. Hum Reprod 2018; 33: 1854-1865
- 35 Weidner K, Neumann A, Siedentopf F. et al. Chronischer Unterbauchschmerz: Die Bedeutung der Schmerzanamnese. Frauenarzt 2015; 56: 982-987
- 36 Hauser W, Bock F, Engeser P. et al. [Recommendations of the updated LONTS guidelines. Long-term opioid therapy for chronic noncancer pain]. Schmerz 2015; 29: 109-130
- 37 Somigliana E, Vigano P, Parazzini F. et al. Association between endometriosis and cancer: a comprehensive review and a critical analysis of clinical and epidemiological evidence. Gynecol Oncol 2006; 101: 331-341
- 38 Kim HS, Kim TH, Chung HH. et al. Risk and prognosis of ovarian cancer in women with endometriosis: a meta-analysis. Br J Cancer 2014; 110: 1878-1890
- 39 Zafrakas M, Grimbizis G, Timologou A. et al. Endometriosis and ovarian cancer risk: a systematic review of epidemiological studies. Front Surg 2014; 1: 14
- 40 Thomsen LH, Schnack TH, Buchardi K. et al. Risk factors of epithelial ovarian carcinomas among women with endometriosis: a systematic review. Acta Obstet Gynecol Scand 2017; 96: 761-778
- 41 Chen LC, Hsu JW, Huang KL. et al. Risk of developing major depression and anxiety disorders among women with endometriosis: A longitudinal follow-up study. J Affect Disord 2016; 190: 282-285
- 42 Evans S, Fernandez S, Olive L. et al. Psychological and mind-body interventions for endometriosis: A systematic review. J Psychosom Res 2019; 124: 109756
- 43 Lagana AS, La Rosa VL, Rapisarda AMC. et al. Anxiety and depression in patients with endometriosis: impact and management challenges. Int J Womens Health 2017; 9: 323-330
- 44 Coloma JL, Martinez-Zamora MA, Collado A. et al. Prevalence of fibromyalgia among women with deep infiltrating endometriosis. Int J Gynaecol Obstet 2019; 146: 157-163
- 45 Veasley: Chronic overlapping Pain Conditions. In: Häuser W, Perrot S. eds. Fibromyalgia Syndrome and Widespread Pain: From Construction to Relevant Recognition. Alphen aan den Rijn: Wolters Kluwer; 2018: 87-111
- 46 Wu CC, Chung SD, Lin HC. Endometriosis increased the risk of bladder pain syndrome/interstitial cystitis: a population-based study. Neurourol Urodyn 2018; 37: 1413-1418
- 47 Schweppe KW, Ebert AD, Kiesel L. Endometriosezentren und Qualitätsmanagement. Gynäkologe 2010; 43: 233-240 doi:10.1007/s00129-009-2484-x
- 48 Rahmenkonzept zur Nachsorge für medizinische Rehabilitation nach § 15 SGB VI der Deutschen Rentenversicherung. Stand: Juni 2015 (in der Fassung vom 1. Juli 2019). Accessed October 31, 2019 at: https://www.deutsche-rentenversicherung.de/SharedDocs/Downloads/DE/Experten/infos_reha_einrichtungen/konzepte_systemfragen/konzepte/rahmenkonzept_reha_nachsorge.pdf?__blob=publicationFile&v=4
- 49 Kofahl C. [Collective patient centeredness and patient involvement through self-help groups]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2019; 62: 3-9
- 50 Hundertmark-Mayser J, Möller-Bock B. Selbsthilfe im Gesundheitsbereich. Gesundheitsberichterstattung des Bundes, Heft 23. Herausgegeben vom Robert-Koch-Institut am 1. August 2004. Accessed October 31, 2019 at: http://www.gbe-bund.de/pdf/Heft23.pdf
Correspondence/Korrespondenzadresse
Publication History
Received: 26 January 2021
Received: 30 January 2021
Accepted: 01 February 2021
Article published online:
14 April 2021
© 2021. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References/Literatur
- 1 Sampson JA. Metastatic or Embolic Endometriosis, due to the Menstrual Dissemination of Endometrial Tissue into the Venous Circulation. Am J Pathol 1927; 3: 93-110.43
- 2 Meyer R. Über den Stand der Frage der Adenomyositis, Adenomyome im allgemeinen und insbesondere über Adenomyositis seroepithelialis und Adenomyometritis sarcomatosa. Zentralbl Gynäkol 1919; 36: 745-750
- 3 Leyendecker G, Kunz G, Noe M. et al. Endometriosis: a dysfunction and disease of the archimetra. Hum Reprod Update 1998; 4: 752-762
- 4 Leyendecker G, Wildt L, Mall G. The pathophysiology of endometriosis and adenomyosis: tissue injury and repair. Arch Gynecol Obstet 2009; 280: 529-538
- 5 Gordts S, Koninckx P, Brosens I. Pathogenesis of deep endometriosis. Fertil Steril 2017; 108: 872-885.e1
- 6 Koninckx PR, Ussia A, Adamyan L. et al. Pathogenesis of endometriosis: the genetic/epigenetic theory. Fertil Steril 2019; 111: 327-340
- 7 Parazzini F, Esposito G, Tozzi L. et al. Epidemiology of endometriosis and its comorbidities. Eur J Obstet Gynecol Reprod Biol 2017; 209: 3-7
- 8 Hirsch M, Begum MR, Paniz E. et al. Diagnosis and management of endometriosis: a systematic review of international and national guidelines. BJOG 2018; 125: 556-564
- 9 Clement PB, Young RH. Atlas of Gynecologic Surgical Pathology. 4th ed. Edinburgh, London, New York, Oxford, Philadelphia, St. Louis, Sydney: Elsevier; 2020: 183-184
- 10 Cockerham AZ. Adenomyosis: a challenge in clinical gynecology. J Midwifery Womens Health 2012; 57: 212-220
- 11 McCluggage WG, Robboy SJ. Mesenchymal uterine tumors, other than pure smooth muscle neoplasms, and adenomyosis. In: Robboyʼs Pathology of the Female Reproductive Tract. 2nd ed.. Churchill Livingstone; 2008: 450-456
- 12 Burghaus S, Fehm T, Fasching PA. et al. The International Endometriosis Evaluation Program (IEEP Study) – A Systematic Study for Physicians, Researchers and Patients. Geburtshilfe Frauenheilkd 2016; 76: 875-881
- 13 Palla VV, Karaolanis G, Katafigiotis I. et al. Ureteral endometriosis: A systematic literature review. Indian J Urol 2017; 33: 276-282
- 14 Schliep KC, Chen Z, Stanford JB. et al. Endometriosis diagnosis and staging by operating surgeon and expert review using multiple diagnostic tools: an inter-rater agreement study. BJOG 2017; 124: 220-229
- 15 Wu D, Hu M, Hong L. et al. Clinical efficacy of add-back therapy in treatment of endometriosis: a meta-analysis. Arch Gynecol Obstet 2014; 290: 513-523
- 16 Tsai HW, Wang PH, Huang BS. et al. Low-dose add-back therapy during postoperative GnRH agonist treatment. Taiwan J Obstet Gynecol 2016; 55: 55-59
- 17 Chaichian S, Kabir A, Mehdizadehkashi A. et al. Comparing the Efficacy of Surgery and Medical Therapy for Pain Management in Endometriosis: A Systematic Review and Meta-analysis. Pain Physician 2017; 20: 185-195
- 18 Zorbas KA, Economopoulos KP, Vlahos NF. Continuous versus cyclic oral contraceptives for the treatment of endometriosis: a systematic review. Arch Gynecol Obstet 2015; 292: 37-43
- 19 Adachi K, Takahashi K, Nakamura K. et al. Postoperative administration of dienogest for suppressing recurrence of disease and relieving pain in subjects with ovarian endometriomas. Gynecol Endocrinol 2016; 32: 646-649
- 20 Zheng Q, Mao H, Xu Y. et al. Can postoperative GnRH agonist treatment prevent endometriosis recurrence? A meta-analysis. Arch Gynecol Obstet 2016; 294: 201-207
- 21 Marjoribanks J, Ayeleke RO, Farquhar C. et al. Nonsteroidal anti-inflammatory drugs for dysmenorrhoea. Cochrane Database Syst Rev 2015; (07) CD001751 DOI: 10.1002/14651858.CD001751.pub3.
- 22 Keyhan S, Hughes C, Price T. et al. An Update on Surgical versus Expectant Management of Ovarian Endometriomas in Infertile Women. Biomed Res Int 2015; 2015: 204792
- 23 Tao X, Chen L, Ge S. et al. Weigh the pros and cons to ovarian reserve before stripping ovarian endometriomas prior to IVF/ICSI: A meta-analysis. PLoS One 2017; 12: e0177426
- 24 Riley KA, Benton AS, Deimling TA. et al. Surgical Excision Versus Ablation for Superficial Endometriosis-Associated Pain: A Randomized Controlled Trial. J Minim Invasive Gynecol 2019; 26: 71-77
- 25 Angioni S, Nappi L, Pontis A. et al. Dienogest. A possible conservative approach in bladder endometriosis. Results of a pilot study. Gynecol Endocrinol 2015; 31: 406-408
- 26 Ceccaroni M, Clarizia R, Ceccarello M. et al. Total laparoscopic bladder resection in the management of deep endometriosis: “take it or leave it.” Radicality versus persistence. Int Urogynecol J 2019; DOI: 10.1007/s00192-019-04107-4.
- 27 Knabben L, Imboden S, Fellmann B. et al. Urinary tract endometriosis in patients with deep infiltrating endometriosis: prevalence, symptoms, management, and proposal for a new clinical classification. Fertil Steril 2015; 103: 147-152
- 28 Hjordt Hansen MV, Dalsgaard T, Hartwell D. et al. Reproductive prognosis in endometriosis. A national cohort study. Acta Obstet Gynecol Scand 2014; 93: 483-489
- 29 Kim SG, Seo HG, Kim YS. Primiparous singleton women with endometriosis have an increased risk of preterm birth: Meta-analyses. Obstet Gynecol Sci 2017; 60: 283-288
- 30 Conti N, Cevenini G, Vannuccini S. et al. Women with endometriosis at first pregnancy have an increased risk of adverse obstetric outcome. J Matern Fetal Neonatal Med 2015; 28: 1795-1798
- 31 Berlac JF, Hartwell D, Skovlund CW. et al. Endometriosis increases the risk of obstetrical and neonatal complications. Acta Obstet Gynecol Scand 2017; 96: 751-760
- 32 Zullo F, Spagnolo E, Saccone G. et al. Endometriosis and obstetrics complications: a systematic review and meta-analysis. Fertil Steril 2017; 108: 667-672.e5
- 33 Vigano P, Corti L, Berlanda N. Beyond infertility: obstetrical and postpartum complications associated with endometriosis and adenomyosis. Fertil Steril 2015; 104: 802-812
- 34 Lalani S, Choudhry AJ, Firth B. et al. Endometriosis and adverse maternal, fetal and neonatal outcomes, a systematic review and meta-analysis. Hum Reprod 2018; 33: 1854-1865
- 35 Weidner K, Neumann A, Siedentopf F. et al. Chronischer Unterbauchschmerz: Die Bedeutung der Schmerzanamnese. Frauenarzt 2015; 56: 982-987
- 36 Hauser W, Bock F, Engeser P. et al. [Recommendations of the updated LONTS guidelines. Long-term opioid therapy for chronic noncancer pain]. Schmerz 2015; 29: 109-130
- 37 Somigliana E, Vigano P, Parazzini F. et al. Association between endometriosis and cancer: a comprehensive review and a critical analysis of clinical and epidemiological evidence. Gynecol Oncol 2006; 101: 331-341
- 38 Kim HS, Kim TH, Chung HH. et al. Risk and prognosis of ovarian cancer in women with endometriosis: a meta-analysis. Br J Cancer 2014; 110: 1878-1890
- 39 Zafrakas M, Grimbizis G, Timologou A. et al. Endometriosis and ovarian cancer risk: a systematic review of epidemiological studies. Front Surg 2014; 1: 14
- 40 Thomsen LH, Schnack TH, Buchardi K. et al. Risk factors of epithelial ovarian carcinomas among women with endometriosis: a systematic review. Acta Obstet Gynecol Scand 2017; 96: 761-778
- 41 Chen LC, Hsu JW, Huang KL. et al. Risk of developing major depression and anxiety disorders among women with endometriosis: A longitudinal follow-up study. J Affect Disord 2016; 190: 282-285
- 42 Evans S, Fernandez S, Olive L. et al. Psychological and mind-body interventions for endometriosis: A systematic review. J Psychosom Res 2019; 124: 109756
- 43 Lagana AS, La Rosa VL, Rapisarda AMC. et al. Anxiety and depression in patients with endometriosis: impact and management challenges. Int J Womens Health 2017; 9: 323-330
- 44 Coloma JL, Martinez-Zamora MA, Collado A. et al. Prevalence of fibromyalgia among women with deep infiltrating endometriosis. Int J Gynaecol Obstet 2019; 146: 157-163
- 45 Veasley: Chronic overlapping Pain Conditions. In: Häuser W, Perrot S. eds. Fibromyalgia Syndrome and Widespread Pain: From Construction to Relevant Recognition. Alphen aan den Rijn: Wolters Kluwer; 2018: 87-111
- 46 Wu CC, Chung SD, Lin HC. Endometriosis increased the risk of bladder pain syndrome/interstitial cystitis: a population-based study. Neurourol Urodyn 2018; 37: 1413-1418
- 47 Schweppe KW, Ebert AD, Kiesel L. Endometriosezentren und Qualitätsmanagement. Gynäkologe 2010; 43: 233-240 doi:10.1007/s00129-009-2484-x
- 48 Rahmenkonzept zur Nachsorge für medizinische Rehabilitation nach § 15 SGB VI der Deutschen Rentenversicherung. Stand: Juni 2015 (in der Fassung vom 1. Juli 2019). Accessed October 31, 2019 at: https://www.deutsche-rentenversicherung.de/SharedDocs/Downloads/DE/Experten/infos_reha_einrichtungen/konzepte_systemfragen/konzepte/rahmenkonzept_reha_nachsorge.pdf?__blob=publicationFile&v=4
- 49 Kofahl C. [Collective patient centeredness and patient involvement through self-help groups]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2019; 62: 3-9
- 50 Hundertmark-Mayser J, Möller-Bock B. Selbsthilfe im Gesundheitsbereich. Gesundheitsberichterstattung des Bundes, Heft 23. Herausgegeben vom Robert-Koch-Institut am 1. August 2004. Accessed October 31, 2019 at: http://www.gbe-bund.de/pdf/Heft23.pdf
![](https://www.thieme-connect.de/media/gebfra/202104/thumbnails/10-1055-a-1380-3693-i13803693gf01.jpg)
![Zoom Image](/products/assets/desktop/css/img/icon-figure-zoom.png)
![](https://www.thieme-connect.de/media/gebfra/202104/thumbnails/10-1055-a-1380-3693-igf_ll.jpg)
![Zoom Image](/products/assets/desktop/css/img/icon-figure-zoom.png)
![](https://www.thieme-connect.de/media/gebfra/202104/thumbnails/10-1055-a-1380-3693-i13803693gfde01.jpg)
![Zoom Image](/products/assets/desktop/css/img/icon-figure-zoom.png)
![](https://www.thieme-connect.de/media/gebfra/202104/thumbnails/10-1055-a-1380-3693-igf_ll.jpg)
![Zoom Image](/products/assets/desktop/css/img/icon-figure-zoom.png)